- Home
- PRK vs MLTX Comparison
PRK vs MLTX Comparison
Compare PRK & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRK
- MLTX
- Stock Information
- Founded
- PRK 1908
- MLTX 2021
- Country
- PRK United States
- MLTX Switzerland
- Employees
- PRK N/A
- MLTX N/A
- Industry
- PRK Major Banks
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- PRK Finance
- MLTX Health Care
- Exchange
- PRK Nasdaq
- MLTX Nasdaq
- Market Cap
- PRK 2.8B
- MLTX 2.3B
- IPO Year
- PRK N/A
- MLTX N/A
- Fundamental
- Price
- PRK $143.82
- MLTX $38.33
- Analyst Decision
- PRK Hold
- MLTX Strong Buy
- Analyst Count
- PRK 1
- MLTX 8
- Target Price
- PRK $178.00
- MLTX $80.50
- AVG Volume (30 Days)
- PRK 66.1K
- MLTX 489.2K
- Earning Date
- PRK 04-29-2025
- MLTX 05-06-2025
- Dividend Yield
- PRK 3.30%
- MLTX N/A
- EPS Growth
- PRK 19.49
- MLTX N/A
- EPS
- PRK 9.32
- MLTX N/A
- Revenue
- PRK $506,064,000.00
- MLTX N/A
- Revenue This Year
- PRK $7.13
- MLTX $103.42
- Revenue Next Year
- PRK $3.46
- MLTX N/A
- P/E Ratio
- PRK $15.43
- MLTX N/A
- Revenue Growth
- PRK 9.34
- MLTX N/A
- 52 Week Low
- PRK $123.31
- MLTX $31.42
- 52 Week High
- PRK $207.99
- MLTX $58.26
- Technical
- Relative Strength Index (RSI)
- PRK 40.72
- MLTX 51.82
- Support Level
- PRK $139.81
- MLTX $31.90
- Resistance Level
- PRK $145.75
- MLTX $37.73
- Average True Range (ATR)
- PRK 5.86
- MLTX 2.99
- MACD
- PRK 0.06
- MLTX 0.29
- Stochastic Oscillator
- PRK 33.97
- MLTX 74.53
About PRK Park National Corporation
Park National Corp is a diversified financial services company based in Newark, Ohio, consisting of 11 community banking divisions with more than 100 offices in Ohio and Kentucky. Park National provides banking and other financial services to consumers and businesses.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.